retatrutide safety profile clinical trials Safety, Side Effects & Provider Use Efficacy and safety of retatrutide,

That means the pill will likely be submitted for FDA approval by mid-2026 and potentially approved by later next year or early 2027

PMC: PMC11226645

thus, tretinate, isotretinoin (Accutane), and other retinoids should not be used during pregnancy or if there is a possibility of becoming pregnant (73)

Retatrutide is a triple agonist, activating GLP-1, GIP, and glucagon receptors simultaneously

There is no clinical evidence demonstrating that compounded versions produce equivalent therapeutic effects or safety profiles

Given the high prevalence of long COVID among diabetic patients, clinicians may consider SGLT2 inhibitors as a preferred option in patients at risk for post-viral complications, particularly individuals with additional risk factors such as obesity and cardiovascular disease